Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
MGP MGM Growth Properties LLC
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Closing Price
$164.96
Day's Change
-2.12 (-1.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
167.08
Day's Low
164.22
Volume
(Average)
Volume:
7,389,922

10-day average volume:
6,860,986
7,389,922

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action and Application Deadline, Encourages Investors with Losses to Contact Its Attorneys Now

9:52 pm ET May 3, 2021 (Globe Newswire) Print

Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.

Class Period: June 15, 2020 - Apr. 4, 2021

Lead Plaintiff Deadline: June 18, 2021

Visit: www.hbsslaw.com/investor-fraud/ACAD

Contact An Attorney Now: ACAD@hbsslaw.com

844-916-0895

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:

The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application ("sNDA") for NUPLAZID(R) (pimavanserin), which treats dementia-related psychosis ("DRP").

Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo. Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug's efficacy.

But the truth began to emerge on Mar. 8, 2021, when Acadia announced that on Mar. 3, 2021 the FDA informed the company that it had identified deficiencies in the sNDA.

Then, on Apr. 5, 2021, Acadia announced the FDA had rejected the sNDA, citing a lack of statistical significance regarding some of the subgroups of dementia and inadequate numbers of patients with some less common dementia subtypes.

"We're focused on investors' losses and proving Acadia misled investors by concealing FDA-related review risks for the sNDA," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are an Acadia investor and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Acadia should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ACAD@hbsslaw.com.

About Hagens Berman

Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844

https://ml.globenewswire.com/media/51670c91-d369-4a8c-8102-d393de9f6d19/small/download-jpg.jpg

https://ml.globenewswire.com/media/51670c91-d369-4a8c-8102-d393de9f6d19/small/download-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.